Cargando…
Chinese Medicine Formula Huashibaidu Granule Early Treatment for Mild COVID-19 Patients: An Unblinded, Cluster-Randomized Clinical Trial
Background: Previous research suggested that Chinese Medicine (CM) Formula Huashibaidu granule might shorten the disease course in coronavirus disease 2019 (COVID-19) patients. This research aimed to investigate the early treatment effect of Huashibaidu granule in well-managed patients with mild COV...
Autores principales: | Zhao, Chen, Li, Li, Yang, Wei, Lv, Wenliang, Wang, Jian, Guo, Jing, Dong, Yu, Shi, Nannan, Lu, Cheng, Li, Zhiqiang, Shi, Zhan, Chen, Renbo, Huo, Ruili, Che, Qianzi, Tian, Yaxin, Xiang, Xinghua, Zhou, Junhui, Bian, Yongjun, Chen, Suping, Chen, Yang, Chen, Yingying, Cong, Xiaodong, Dong, Guoju, Hu, Lijie, Jiang, Jianxin, Leng, Luxing, Li, Bin, Li, Dongxu, Li, Hao, Li, Jing, Qi, Wensheng, Miao, Qing, Shi, Huaxin, Shi, Jiaheng, Wang, Bing, Wang, Gang, Wang, Wei, Xian, Yongyue, Xie, Xiaolei, Xu, Chunyan, Xu, Ming, Yan, Bei, Yang, Jinliang, Zhang, Li, Zhou, Zhenqi, Zhu, Haoning, Xiong, Yibai, Liu, Bin, Huang, Luqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481869/ https://www.ncbi.nlm.nih.gov/pubmed/34604251 http://dx.doi.org/10.3389/fmed.2021.696976 |
Ejemplares similares
-
Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial
por: Shi, Nannan, et al.
Publicado: (2021) -
Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): A single-center, open-label, randomized controlled trial
por: Liu, Jia, et al.
Publicado: (2021) -
The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19: A retrospective cohort study
por: Xiong, Yibai, et al.
Publicado: (2022) -
Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial
por: Chen, Bowu, et al.
Publicado: (2023) -
Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19
por: Zhang, Fangbo, et al.
Publicado: (2023)